ClinVar Miner

Submissions for variant NM_000090.3(COL3A1):c.754G>T (p.Gly252Cys) (rs587779705)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000222891 SCV000271211 likely pathogenic Ehlers-Danlos syndrome, type 4 2015-04-06 criteria provided, single submitter clinical testing The p.Gly252Cys variant has not been previously reported in individuals with cli nical features of Ehlers-Danlos syndrome type IV (EDS IV) and it was absent from large population studies. However, other variants affecting the same residue ha ve been reported in more than 9 affected individuals (p.Gly252Arg, p.Gly252Asp, p.Gly252Val; Pepin 2000, Kerwin 2008, Muller 2011, Ferre 2011, Pepin 2014, Frank 2015). Computational prediction tools and conservation analysis suggest that th e p.Gly252Cys variant may impact the protein. Variants in COL3A1 affecting conse rved glycine (Gly) residues of the G-X-Y repeat region in the triple helical col lagen domain are strongly associated with EDS IV (Pepin 2000, Pepin 2014, Frank 2015), where this variant is located. In summary, although additional studies ar e required to fully establish its clinical significance, the p.Gly252Cys variant is likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.